Saturday 31 October 2020 ,
Latest News
18 October, 2020 04:49:21 PM

Print

Russian Covid-19 vaccine Sputnik V gets nod for clinical trial in India

BSS, New Delhi
Russian Covid-19 vaccine Sputnik V gets nod for clinical trial in India

Sputnik V, the world’s first registered vaccine developed by Russia against Covid-19, has been approved for conducting an adaptive phase 2 and 3 trial in India.

This was announced in a joint statement by Dr Reddys Laboratories Ltd, a multinational pharmaceutical company in India and the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, on Saturday.

The statement said that Dr Reddys Laboratory and RDIF have received approval from the Drug Control General of India to conduct “an adaptive phase 2 and 3 clinical trial for Sputnik V vaccine in India”.

This will be a multi-centre and randomised controlled study, which will include safety and immunogenicity study, it said.

Earlier in September 2020, Dr Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India.

As part of the partnership, RDIF is set to supply 100 million doses of the vaccine to Dr Reddys upon regulatory approval in India, an IANS, an Independent Newswire, report said here yesterday.

Quoting the statement, the report said that the deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.

“The agreement between RDIF and Dr Reddy’s reflects the growing awareness of countries and organizations to have a diversified anti-COVID vaccine portfolio to protect their populations,” it added. G V Prasad, Co-chairman and Managing Director, Dr Reddy’s, said, “This is a significant development that allows us to commence the clinical trial in India and we are committed to bringing in a safe and efficacious vaccine to combat the pandemic.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund said, “We are pleased to collaborate with the Indian regulators and in addition to Indian clinical trial data, we will provide safety and immunogenicity study from the Russian phase 3 clinical trial.”

On August 11, 2020, Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19 based on the human adenoviral vectors platform.

Sputnik V is currently undergoing phase 3 clinical trials in Russia. Besides, the phase 3 clinical trial of the vaccine commenced in the UAE last week, the IANS report said.

BK

Comments

Poll
Today's Question »
State minister for power Nasrul Hamid yesterday said everyone to have access to electricity by June. Do you think the feat achievable by the timeframe?
 Yes
 No
 No Comment
Yes 47.3%
No 48.7%
No Comment 4.1%
Video

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting